Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non–Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery?

Hiroshi Onishi; Hiroki Shirato; Yasushi Nagata; Masahiro Hiraoka; Masaharu Fujino; Kotaro Gomi; Katsuyuki Karasawa; Kazushige Hayakawa; Yuzuru Niibe; Yoshihiro Takai; Tomoki Kimura; Atsuya Takeda; Atsushi Ouchi; Masato Hareyama; Masaki Kokubo; Takuyo Kozuka; Takuro Arimoto; Ryusuke Hara; Jun Itami; Tsutomu Araki; Fang-Hsin Chen

doi:10.1016/j.ijrobp.2009.07.1751

Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non–Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery?

Hiroshi Onishi, Hiroki Shirato, Yasushi Nagata, Masahiro Hiraoka, Masaharu Fujino, Kotaro Gomi, Katsuyuki Karasawa, Kazushige Hayakawa, Yuzuru Niibe, Yoshihiro Takai, …

International journal of radiation oncology, biology, physics, Vol.81(5), pp.1352-1358

01/12/2011

: https://doi.org/10.1016/j.ijrobp.2009.07.1751

: 20638194

: WOS:000297602400021

Lung cancer

Non–small-cell

Operable

Stage I

Stereotactic body radiotherapy

To review treatment outcomes for stereotactic body radiotherapy (SBRT) in medically operable patients with Stage I non–small-cell lung cancer (NSCLC), using a Japanese multi-institutional database. Between 1995 and 2004, a total of 87 patients with Stage I NSCLC (median age, 74 years; T1N0M0, n = 65; T2N0M0, n = 22) who were medically operable but refused surgery were treated using SBRT alone in 14 institutions. Stereotactic three-dimensional treatment was performed using noncoplanar dynamic arcs or multiple static ports. Total dose was 45–72.5 Gy at the isocenter, administered in 3–10 fractions. Median calculated biological effective dose was 116 Gy (range, 100–141 Gy). Data were collected and analyzed retrospectively. During follow-up (median, 55 months), cumulative local control rates for T1 and T2 tumors at 5 years after SBRT were 92% and 73%, respectively. Pulmonary complications above Grade 2 arose in 1 patient (1.1%). Five-year overall survival rates for Stage IA and IB subgroups were 72% and 62%, respectively. One patient who developed local recurrences safely underwent salvage surgery. Stereotactic body radiotherapy is safe and promising as a radical treatment for operable Stage I NSCLC. The survival rate for SBRT is potentially comparable to that for surgery.

: Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non–Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery?
: Hiroshi Onishi - University of Yamanashi
Hiroki Shirato - Hokkaido University
Yasushi Nagata - Hiroshima University
Masahiro Hiraoka - Kyoto University
Masaharu Fujino - Hokkaido University
Kotaro Gomi - Suwa Red Cross Hospital
Katsuyuki Karasawa - Tokyo Metropolitan Komagome Hospital
Kazushige Hayakawa - Kitasato University
Yuzuru Niibe - Kitasato University Hospital
Yoshihiro Takai - Hirosaki University
Tomoki Kimura - Kagawa University
Atsuya Takeda - Gunma Chuo Hospital
Atsushi Ouchi - Teine Keijinkai Hospital
Masato Hareyama - Sapporo Medical University
Masaki Kokubo - Foundation for Biomedical Research and Innovation
Takuyo Kozuka - The Cancer Institute Hospital
Takuro Arimoto - Japanese Red Cross Hokkaido College of Nursing
Ryusuke Hara - National Institute of Radiological Science, Chiba, Japan
Jun Itami - National Cancer Center, Tokyo, Japan
Tsutomu Araki - University of Yamanashi
Fang-Hsin Chen - National Tsing Hua University, Institute of Nuclear Engineering and Science
: Elsevier Inc
: 7
: Ministry of Health, Welfare and Labor of Japan
: Journal article
: 01/12/2011
: International journal of radiation oncology, biology, physics, Vol.81(5), pp.1352-1358
: English